Latest Stocks: Suntrust Banks Inc. Sells 11 Shares of Regeneron Pharmaceuticals Inc (REGN)

Latest Stocks: Suntrust Banks Inc. Sells 11 Shares of Regeneron Pharmaceuticals Inc (REGN)

Suntrust Banks Inc. lowered its position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 0.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,135 shares of the biopharmaceutical company’s stock after selling 11 shares during the period. Suntrust Banks Inc.’s holdings in Regeneron Pharmaceuticals were worth $1,213,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Bank of New York Mellon Corp boosted its stake in Regeneron Pharmaceuticals by 36.8% in the first quarter. Bank of New York Mellon Corp now owns 881,867 shares of the biopharmaceutical company’s stock worth $341,733,000 after buying an additional 237,157 shares during the last quarter. Checchi Capital Advisers LLC boosted its stake in shares of Regeneron Pharmaceuticals by 4.9% in the first quarter. Checchi Capital Advisers LLC now owns 626 shares of the biopharmaceutical company’s stock valued at $243,000 after buying an additional 29 shares in the last quarter. HPM Partners LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter valued at $1,894,000. Henderson Group PLC boosted its stake in shares of Regeneron Pharmaceuticals by 2.0% in the first quarter. Henderson Group PLC now owns 10,022 shares of the biopharmaceutical company’s stock valued at $3,883,000 after buying an additional 200 shares in the last quarter. Finally, Sheaff Brock Investment Advisors LLC boosted its stake in shares of Regeneron Pharmaceuticals by 1.4% in the first quarter. Sheaff Brock Investment Advisors LLC now owns 750 shares of the biopharmaceutical company’s stock valued at $291,000 after buying an additional 10 shares in the last quarter. 68.83% of the stock is owned by institutional investors and hedge funds.

Shares of Regeneron Pharmaceuticals Inc (REGN) opened at 480.26 on Tuesday. The company’s 50 day moving average is $424.17 and its 200 day moving average is $386.91. The company has a market capitalization of $50.70 billion, a price-to-earnings ratio of 58.14 and a beta of 1.44. Regeneron Pharmaceuticals Inc has a one year low of $325.35 and a one year high of $489.00.

Several analysts have recently commented on the stock. Sanford C. Bernstein reissued an “outperform” rating on shares of Regeneron Pharmaceuticals in a research note on Thursday, May 25th. Vetr lowered shares of Regeneron Pharmaceuticals from a “sell” rating to a “strong sell” rating and set a $368.84 target price on the stock. in a report on Monday, May 15th. BMO Capital Markets increased their target price on shares of Regeneron Pharmaceuticals from $412.00 to $421.00 and gave the stock a “hold” rating in a report on Monday, May 15th. Cowen and Company reissued a “hold” rating and set a $380.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Monday, May 15th. Finally, Credit Suisse Group AG reissued a “buy” rating and set a $485.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Monday, May 15th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating and twelve have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $432.21. In related news, EVP Neil Stahl sold 2,812 shares of the business’s stock in a transaction that occurred on Friday, June 2nd. The stock was sold at an average price of $479.49, for a total transaction of $1,348,325.88. Following the completion of the transaction, the executive vice president now directly owns 28,477 shares in the company, valued at approximately $13,654,436.73. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Chairman P Roy Vagelos sold 9,295 shares of the business’s stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $458.14, for a total value of $4,258,411.30. Following the completion of the transaction, the chairman now directly owns 414,156 shares in the company, valued at $189,741,429.84. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 16,107 shares of company stock valued at $7,356,737. 10.40% of the stock is currently owned by corporate insiders.

Receive News & Ratings for Regeneron Pharmaceuticals Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Regeneron Pharmaceuticals Inc and related companies with MarketBeat.com’s FREE daily email newsletter.

Related posts

Leave a Comment